🔴 Citius Pharmaceuticals is trading 11.86% down in after-hours trading after citing substantial additional funding needs

Citius Pharmaceuticals is trading at $0.67 (-11.86%) in after-hours trading after reporting an $8.9 million quarterly net loss and substantial funding needs.

• Reported $1.5 million in fiscal third-quarter revenue as LYMPHIR adoption expanded.
• Held $17.0 million in cash and said it needs substantial additional funding to support operations for at least twelve months.
• The loss is likely to intensify financing and dilution concerns despite improving commercialization.